Celecoxib / eff Cancer Research Results

CEL, Celecoxib: Click to Expand ⟱

Features: NSAID

Celecoxib inhibits the formation of prostaglandins: used primarily to treat pain and other symptoms of osteoarthritis, rheumatoid arthritis, joint and musculoskeletal conditions.

Celecoxib is a diaryl-substituted selective cyclooxygenase-2 inhibitor that lowers prostaglandin synthesis and is used clinically as an oral nonsteroidal anti-inflammatory drug. It is formally classified as a small-molecule NSAID and COX-2–preferential inhibitor. Standard abbreviations include celecoxib and CEL. In oncology, its main rationale is suppression of the COX-2/PGE2 inflammatory-tumor axis, with additional COX-2-independent effects reported at higher experimental concentrations, including interference with PDK1/Akt signaling, ER calcium handling, and stress-linked apoptosis pathways. Nestronics lists it as an NSAID and currently indexes mainly EMT, HIF-1α/VEGF, COX-2, NF-κB, p65, and TGF-β/SMAD3-related findings.

Primary mechanisms (ranked):

COX-2 inhibition with reduced PGE2 signaling and downstream inflammatory, proliferative, angiogenic, and immune-evasive tumor support
Suppression of NF-κB-linked inflammatory survival programs
Reduction of hypoxia/angiogenesis signaling including HIF-1α and VEGF in relevant models
Partial inhibition of PDK1/Akt survival signaling in some tumor systems
COX-2-independent ER stress and Ca²⁺ dysregulation via SERCA-related effects at supratherapeutic or high in-vitro concentrations
Contextual chemosensitization, including effects on apoptosis threshold and in some reports drug-resistance programs such as P-gp
Possible ancillary carbonic anhydrase inhibition is mechanistically interesting but not established as the dominant clinical anticancer mechanism

Bioavailability / PK relevance: Celecoxib is orally active. Peak plasma levels occur at about 3 hours, effective half-life is about 11 hours, steady state is reached by about day 5, and the drug is highly protein bound. Exposure is roughly dose-proportional up to 200 mg twice daily, with less-than-proportional increases above that range because of solubility limits. It is metabolized mainly by CYP2C9, so poor metabolizers and strong CYP2C9 interactions are clinically relevant.

In-vitro vs systemic exposure relevance: This is an important translation constraint. Many direct pro-apoptotic, SERCA/ER-stress, and stronger Akt-related anticancer effects are reported in vitro at concentrations commonly above those readily achievable with standard anti-inflammatory dosing. By contrast, COX-2/PGE2 suppression is clearly clinically reachable and is the most exposure-plausible core mechanism. Therefore, low- to mid-micromolar inflammatory and microenvironment effects are more translatable than high-concentration cytotoxic claims.

Clinical evidence status: Strong clinical deployment exists for pain/inflammatory indications, not for cancer treatment. In oncology, evidence is mixed: extensive preclinical support, some small human and adjunct studies, but major randomized adjuvant trials in unselected breast and stage III colon cancer were negative overall. A more recent biomarker-defined signal has emerged in PIK3CA-activated stage III colon cancer, where celecoxib appeared beneficial in subgroup analysis, so any cancer role currently looks biomarker- and context-dependent rather than broadly established.

Mechanistic table

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	COX-2 / PGE2 inflammatory signaling	COX-2 activity ↓; PGE2 tone ↓; proliferation, survival, invasion, immune evasion ↓	Inflammatory prostaglandin signaling ↓	R/G	Core anti-inflammatory antitumor mechanism	Best-supported and most clinically reachable mechanism; strongest translational anchor for oncology repurposing
2	NF-κB inflammatory survival axis	NF-κB/p65 ↓; inflammatory survival transcription ↓	Inflammatory signaling ↓	R/G	Reduced survival and inflammatory tone	Consistent with Nestronics and broader literature; partly downstream of reduced PGE2 but may also reflect parallel signaling effects
3	HIF-1α / VEGF angiogenesis axis	HIF-1α ↓; VEGF ↓; angiogenic support ↓	↔ or angiogenic signaling ↓ in inflammatory settings	G	Antiangiogenic pressure	Likely relevant in hypoxic and COX-2-high tumors; fits both Nestronics indexing and broader COX-2/PGE2 biology
4	TGF-β / SMAD3 / EMT	TGF-β ↓; SMAD3 ↓; EMT ↓; migration/invasion ↓	↔	G	Anti-migratory and anti-invasive effect	Nestronics support is specific here; likely more tumor-contextual than universally dominant
5	PDK1 / Akt survival signaling	PDK1/Akt ↓ (context-dependent); apoptosis threshold ↓	↔	R/G	COX-independent survival suppression	Mechanistically important in the celecoxib literature, but many strong effects are reported at higher in-vitro concentrations
6	Ca²⁺ homeostasis and ER stress	ER Ca²⁺ reuptake ↓; cytosolic Ca²⁺ stress ↑; ER stress/apoptosis ↑	Potential stress if exposure is high enough	P/R	Stress-triggered apoptosis	Usually linked to SERCA interference and considered mainly a high-concentration or COX-independent mechanism
7	Mitochondrial apoptosis program	Caspase activation ↑; Bcl-2-family survival balance shifts toward apoptosis	↔	R/G	Apoptotic execution	Generally downstream of Akt inhibition, ER stress, or combined treatment sensitization rather than the first initiating event
8	Chemosensitization	Drug sensitivity ↑; apoptosis with cytotoxics ↑	Potential inflammation/pain benefit in host context	G	Adjunctive therapy potential	Observed preclinically and in some clinical adjunct settings, but not confirmed as a broad survival-improving strategy in unselected populations
9	P-gp and resistance signaling	P-gp ↓ (model-dependent); intracellular drug retention ↑	↔	G	Possible reversal of drug resistance	Interesting but not core; should be treated as secondary and context-specific
10	Carbonic anhydrase inhibition	CA-related pH adaptation ↓ (context-dependent)	Off-target CA interaction possible	↔	Ancillary microenvironment effect	Celecoxib can inhibit carbonic anhydrases, but this is better viewed as a mechanistic side branch than the main oncology rationale for celecoxib itself
11	Clinical Translation Constraint	Overall efficacy signal mixed; biomarker-defined benefit more plausible than broad use	Cardiovascular, renal, GI, and drug-interaction liabilities constrain chronic escalation	G	Limits generalized oncology deployment	Main constraint is that clinically achievable exposure strongly supports COX-2/PGE2 modulation, whereas many direct cytotoxic claims require higher concentrations; major adjuvant trials were negative overall, though PIK3CA-activated colon cancer is a notable exception signal

P: 0–30 min

R: 30 min–3 hr

G: >3 hr

eff, efficacy: Click to Expand ⟱

Source:

Type:

Power to enhance an anti cancer effect

Scientific Papers found: Click to Expand⟱

5960-

CEL,

Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers

Trial,

Pca,

eff∅, Dose↝, CardioT↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Drug Metabolism & Resistance ⓘ

Dose↝, 1, eff∅, 1,

Functional Outcomes ⓘ

CardioT↑, 1,
Total Targets: 3

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: eff, efficacy

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells